Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer

Published version of a preprint

Abstract

Purpose: Systemic androgen-signaling inhibition added to ongoing androgen-deprivation therapy (ADT) improved clinical outcomes in patients with nonmetastatic castration-resistant prostate cancer without detectable metastases by conventional imaging (nmCRPC). Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) detects prostate cancer with superior sensitivity to conventional imaging, but its performance in nmCRPC remains largely unknown. We characterized cancer burden in high-risk patients with nmCRPC using PSMA-PET. Experimental Design: We retrospectively included 200 patients with nmCRPC, prostate-specific antigen (PSA) >2 ng/mL, and high risk for metastatic disease [PSA doubling time (PSADT) of ≤10 months and/or Gleason score of ≥8] from six high-volume PET centers. We centrally reviewed PSMA-PET detection rate for pelvic disease and distant metastases (M1). We further evaluated SPARTAN patients stratified by risk factors for PSMA-PET-detected M1 disease. Results: PSMA-PET was positive in 196 of 200 patients. Overall, 44% had pelvic diseases, including 24% with local prostate bed recurrence, and 55% had M1 disease despite negative conventional imaging. Interobserver agreement was very high (κ: 0.81–0.91). PSA ≥ 5.5 ng/mL, locoregional nodal involvement determined by pathology (pN1), prior primary radiation, and prior salvage radiotherapy independently predicted M1 disease (all P < 0.05). Conclusions: PSMA-PET detected any disease in nearly all patients and M1 disease in 55% of patients previously diagnosed with nmCRPC, including subgroups with PSADT of ≤10 months and Gleason score of ≥8. The value of PSMA-PET imaging for treatment guidance should be tested in future studies.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-1050

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 28 references

Research works printed but not linked: 1

  1. Hope, 2018, Meta-analysis of 68Ga-PSMA-11 PET with a focus on pathology correlation, J Nucl Med, 59, 1714

Cited by

See all 266

Metadata

Authors
Fendler, W. P., Weber, M., Iravani, A., Hofman, M. S., Calais, J., Czernin, J., Ilhan, H., Saad, F., Small, E. J., Smith, M. R., Perez, P. M., Hope, T. A., Rauscher, I., Londhe, A., Lopez-Gitlitz, A., Cheng, S., Maurer, T., Herrmann, K., Eiber, M., & Hadaschik, B.
Affiliations
  • University of California, Los Angeles (US)
  • Essen University Hospital (DE)
  • Peter MacCallum Cancer Centre (AU)
  • Ludwig-Maximilians-Universität München (DE)
  • 5Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Québec, Canada.
  • University of California, San Francisco (US)
  • Harvard University (US)
  • TUM Klinikum (DE)
  • 9Janssen Research & Development, Titusville, New Jersey.
  • 10Janssen Research & Development, Los Angeles, California.
  • Janssen Research & Development (United States) (US)
  • Universität Hamburg (DE)
Venue
Clinical Cancer Research
Published
2019-12-13
Volume
25
Issue
24
Pages
7448-7454
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2972890374
Cited by
266
References
28
Citations by year
2026: 18 · 2025: 27 · 2024: 40 · 2023: 43 · 2022: 41 · 2021: 55 · 2020: 38 · 2019: 3
FWCI
25.19
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Funders
  • German Research Foundation (FE1573/1-1/807122 and FE1573/3-1/659216)
  • Mercator Research Center Ruhr (An-2019-0001)
  • IFORES (D/107-81260, D/107-30240)
Topics
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
prostate-specific membrane antigen, PSMA PET, non-metastatic castration-resistant prostate cancer, distant metastasis, pelvic diseases, androgen deprivation therapy, SPARTAN trial, Gleason score, PSA doubling time, salvage radiotherapy, prior radiation, metastasis detection
MeSH terms
Positron Emission Tomography Computed Tomography, Aged, Aged, 80 and over, Androgen Antagonists, Antigens, Surface, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Retrospective Studies, Radiopharmaceuticals, Glutamate Carboxypeptidase II, Neoplasm Grading, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-1050
The paper
Fendler, W. P., Weber, M., Iravani, A., Hofman, M. S., Calais, J., Czernin, J., Ilhan, H., Saad, F., Small, E. J., Smith, M. R., Perez, P. M., Hope, T. A., Rauscher, I., Londhe, A., Lopez-Gitlitz, A., Cheng, S., Maurer, T., Herrmann, K., Eiber, M., & Hadaschik, B. (2019). Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-1050

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.